Journal ArticleDOI
Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities
TLDR
Exploring the scientific possibilities of new therapies targeting HIV-1 latency may hold new promise of eventual HIV- 1 eradication and warrant further consideration for rational drug design.About:
This article is published in Antiviral Research.The article was published on 2000-12-01. It has received 32 citations till now. The article focuses on the topics: Latency (engineering).read more
Citations
More filters
Journal ArticleDOI
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
TL;DR: Direct sequencing of integration sites demonstrated that latent clones frequently contain HIV integrated in or close to alphoid repeat elements in heterochromatin, demonstrating that HIV can reproducibly establish a latent infection as a consequence of integration in or near heterochROMatin.
Journal ArticleDOI
Hiv infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
TL;DR: The best way to fight HIV-1 disease, therefore, appears to be through prevention and early treatment.
Journal ArticleDOI
Molecular characterization, reactivation, and depletion of latent HIV
David G. Brooks,Dean H. Hamer,Philip A. Arlen,Lianying Gao,Greg Bristol,Christina M. R. Kitchen,Edward A. Berger,Jerome A. Zack +7 more
TL;DR: It is demonstrated that activation of latent virus is required for targeting by antiviral agents and provide the basis for future therapeutic strategies to eradicate the latent reservoir.
Journal ArticleDOI
Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells.
TL;DR: Transcription is a crucial step for human immunodeficiency virus type 1 (HIV‐1) expression in all infected host cells, and knowledge about the molecular mechanisms underlying transcriptional regulatory events helps in the search for therapeutic agents that target the step of transcription in anti‐HIV strategies.
References
More filters
Journal ArticleDOI
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
Frank J. Palella,Kathleen M. Delaney,Anne C. Moorman,Mark O. Loveless,Jack Fuhrer,Glen A. Satten,Diane J. Aschman,Scott D. Holmberg +7 more
TL;DR: The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Journal ArticleDOI
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
TL;DR: A study was conducted to evaluate the impact of protease inhibitors on the rates of selected opportunistic processes and mortality in patients with AIDS and found similar results.
Journal ArticleDOI
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
TL;DR: Treatment of infected patients with ABT-538 causes plasma HIV-1 levels to decrease exponentially and CD4 lymphocyte counts to rise substantially, indicating that replication of HIV- 1 in vivo is continuous and highly productive, driving the rapid turnover ofCD4 lymphocytes.
Journal ArticleDOI
Viral dynamics in human immunodeficiency virus type 1 infection
Xiping Wei,Sajal Ghosh,Maria E. Taylor,Victoria A. Johnson,Emilio A. Emini,Deutsch Paul J,Jeffrey D. Lifson,Sebastian Bonhoeffer,Martin A. Nowak,Beatrice H. Hahn,Michael S. Saag,George M. Shaw +11 more
TL;DR: Almost complete replacement of wild-type virus in plasma by drug-resistant variants occurs after fourteen days, indicating that HIV-1 viraemia is sustained primarily by a dynamic process involving continuous rounds of de novo virus infection and replication and rapid cell turnover.
Journal ArticleDOI
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
Diana Finzi,Monika Hermankova,Theodore C. Pierson,Lucy M. Carruth,Christopher B. Buck,Richard E. Chaisson,Thomas C. Quinn,Karen Chadwick,Joseph B. Margolick,Ron Brookmeyer,Joel E. Gallant,Martin Markowitz,David D. Ho,Douglas D. Richman,Robert F. Siliciano +14 more
TL;DR: In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes, and generally did not show mutations associated with resistance to the relevant antiretroviral drugs.